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COST-EFFECTIVENESS ANALYSIS OF IMMUNIZATION STRATEGIES FOR THE CONTROL OF MENINGOCOCCAL INFECTIOUS DISEASE
Suh HS, Hay JW University of Southern California, Los Angeles, CA, USA OBJECTIVES: To evaluate the cost-effectiveness of three different immunization strategies (1st: one time routine vaccination of all adolescents aged 11 years [yr] , 2nd: college freshmen aged 18 yr, and 3rd: college freshmen living in dormitories aged 18 yr) with meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine [MCV4] compared to no vaccination from a societal perspective. METHODS: A decision analysis model using backward induction method was employed with parameter values from published literature and HCUPnet (Health care Cost and Utilization Project). All subjects were followed until they reached 29 yr-old. Direct costs (vaccine, administration, hospitalization, outbreak control, and lifetime care) and indirect costs (patient and health care workers time cost) were measured in 2005 US$. Effectiveness was measured as quality adjusted life years [QALYs] . All costs and QALYs were discounted at 3% and cost-effectiveness was measured as incremental cost per QALYs gained [ICER] . Uncertainty was evaluated using multiple oneway sensitivity analyses. RESULTS: All strategies yielded favorable ICERs ($16,746, $29,447, and $19,203 for 1st, 2nd , and 3rd strategy, respectively). The results were more favorable when herd immunity was considered ($9916, $18,163, and $11,402 for 1st, 2nd, and 3rd strategy, respectively). All strategies were highly sensitive to the duration of vaccine efficacy and the discount rate. A 50% decrease in these parameter values led to more than a 100% change in ICERs. The herd immunity effect of 25%, 50%, and 75% lead approximately to 25%, 40%, and 50% change in ICERs. The model was sensitive to the disease incidence rate, the risk for sequelae, and the vaccine cost, but not to direct costs for treatment and the vaccine efficacy. CON-CLUSION: Three immunization strategies were cost-effective compared to no vaccination using a societal threshold cut-off of $50,000 per QALY. This analysis shows the opposite result to previous U.S. findings. Further research is needed to explain these discrepancies. To examine the cost-effectiveness of PCV and to determine if there is any long-term cost offset if it became a routine vaccination for infants. METHODS: Two hypothetical cohorts of 1000 infants (one vaccinated and one unvaccinated) were followed over lifetime. A decision analytical model was used to analyze the cost and cost-effectiveness of the vaccine from a government's perspective. The probabilities of events of invasive pneumococcal diseases (IPD) and otitis media (OM) were derived from published local or overseas data. Vaccine efficacy (mid-range) from overseas trials was used. Cost avoidance arising from herd immunity was calculated based on overseas published data. Cost of management of complications arising from pneumococcal infections was estimated from a group of hospitalized or outpatient cases from 2 large regional public hospitals in Hong Kong. The costs associated with non-hospitalized disease states were captured through interviews with a group of identified GPs selected from different regions in Hong Kong. Vaccination programme costs included vaccine acquisition cost and cost of administration. Productivity loss was assessed in terms of extra care from family members, reduced earning ability and early retirement due to disability, absenteeism, and premature death. RESULTS: After a routine four-dose vaccination of infants in their first year of life, the PCV was estimated to have averted 566 cases of IPD and 2562 cases of OM. Using a discount rate of 5% for all projections, the direct and indirect costs per life year gained (CLYG) is HKD94,300 (USD12,090, 1USD = 7.8HKD) and HKD63,000 (USD8077) if no herd effect was included. With herd immunity included, the direct and indirect CLYG is reduced to HKD58,600 (USD7513) and HKD38,000 (USD4890) respectively. CONCLUSION: PCV appears to be cost-saving by averting IPD and related complications and also cost-effective due to herd immunity. (1998-2001) and after (2003-2005 ) the introduction of Prevnar®. The main outcomes analyzed included total cases, quality adjusted life years (QALY), and total cost for health states bacteremia, meningitis, pneumonia, otitis media, myringotomy, and death. Outcomes were based on real-world epidemiology data from Calgary. Resource utilization was derived from a Canadian Institute for Health Information database and, as necessary, from the literature and expert opinion. All costs (in 2006 Canadian dollars) and outcomes were discounted by 3%.
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